Related Experiment Video

Updated: Apr 12, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Dual roles of TLR7 in the lung cancer microenvironment

Marion Dajon1, Kristina Iribarren1, Isabelle Cremer1

  • 1Institut National de la Santé et de la Recherche Médicale (INSERM); UMRS1138; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie-Paris 6; UMRS1138 ; Paris France ; Université Paris Descartes; UMRS1138 ; Paris, France.

Oncoimmunology
|May 8, 2015
PubMed

Insights

Toll-like receptor 7 (TLR7) agonists may boost anti-cancer immunity but can also fuel tumor growth. High TLR7 expression in lung cancer correlates with poor outcomes, suggesting a complex role in cancer progression.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Toll-like receptor 7 (TLR7) agonists are explored for cancer immunotherapy.
  • TLR7 can be expressed on tumor cells, potentially leading to unintended protumorigenic effects.
  • High TLR7 expression is linked to adverse clinical outcomes and chemotherapy resistance in lung cancer.

Purpose of the Study:

  • To investigate the dual role of TLR7 agonists in cancer therapy.
  • To understand the impact of TLR7 expression on tumor cell stimulation and clinical prognosis.
  • To validate the protumorigenic effects of TLR7 in preclinical lung cancer models.

Main Methods:

  • Analysis of TLR7 expression in lung cancer patient tumors.
  • Validation of TLR7 protumorigenic effects in murine models of lung carcinoma.
  • Investigation of TLR7 agonist interactions with tumor cells.

Main Results:

  • High TLR7 expression in primary tumors is associated with poor clinical outcomes.
  • Elevated TLR7 levels correlate with resistance to chemotherapy in lung cancer patients.
  • The protumorigenic role of TLR7 was confirmed in experimental lung carcinoma models.

Conclusions:

  • TLR7 signaling presents a complex therapeutic challenge in lung cancer.
  • Targeting TLR7 requires careful consideration of its potential to promote tumor growth.
  • Further research is needed to delineate TLR7's precise role and optimize its therapeutic application.
Keywords:
MDSCTLR7chemoresistancelung cancer

More Related Videos

Lung Tumor Cell Recruitment Assay04:28

Lung Tumor Cell Recruitment Assay

Published on: February 26, 2019

6.1K
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues07:39

The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues

Published on: June 16, 2018

10.0K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

3.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K